دورية أكاديمية
Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization.
| العنوان: | Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization. |
|---|---|
| المؤلفون: | Ragone C; Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy., Mauriello A; Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy., Cavalluzzo B; Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy., Cavalcanti E; Lab of Clinical Pathology, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy., Russo L; Lab of Clinical Pathology, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy., Manolio C; Clinical and Epidemiological Genetics Unit, Azienda Ospedaliera - University of Padua, Padua, Italy., Mangano S; Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy., Cembrola B; Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy., Tagliamonte M; Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy., Buonaguro L; Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - 'Fond G. Pascale', Naples, Italy. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Jun 14; Vol. 15, pp. 1398002. Date of Electronic Publication: 2024 Jun 14 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | SARS-CoV-2*/immunology , COVID-19*/prevention & control , COVID-19*/immunology , Molecular Mimicry*/immunology , CD8-Positive T-Lymphocytes*/immunology , Cross Reactions*/immunology , Epitopes, T-Lymphocyte*/immunology, Humans ; BNT162 Vaccine/immunology ; Antigens, Viral/immunology ; HLA-A2 Antigen/immunology ; Neoplasms/immunology ; Neoplasms/prevention & control ; Antigens, Neoplasm/immunology ; COVID-19 Vaccines/immunology |
| مستخلص: | Background: In the present study we investigated whether peptides derived from the entire SARS-CoV-2 proteome share homology to TAAs (tumor-associated antigens) and cross-reactive CD8+ T cell can be elicited by the BNT162b2 preventive vaccine or the SARS-CoV-2 natural infection. Methods and Results: Viral epitopes with high affinity (<100nM) to the HLA-A*02:01 allele were predicted. Shared and variant-specific epitopes were identified. Significant homologies in amino acidic sequence have been found between SARS-CoV-2 peptides and multiple TAAs, mainly associated with breast, liver, melanoma and colon cancers. The molecular mimicry of the viral epitopes and the TAAs was found in all viral proteins, mostly the Orf 1ab and the Spike, which is included in the BNT162b2 vaccine. Predicted structural similarities confirmed the sequence homology and comparable patterns of contact with both HLA and TCR α and β chains were observed. CD8+ T cell clones cross-reactive with the paired peptides have been found by MHC class l-dextramer staining. Conclusions: Our results show for the first time that several SARS-COV-2 antigens are highly homologous to TAAs and cross-reactive T cells are identified in infected and BNT162b2 preventive vaccinated individuals. The implication would be that the SARS-Cov-2 pandemic could represent a natural preventive immunization for breast, liver, melanoma and colon cancers. In the coming years, real-world evidences will provide the final proof for such immunological experimental evidence. Moreover, such SARS-CoV-2 epitopes can be used to develop "multi-cancer" off-the-shelf preventive/therapeutic vaccine formulations, with higher antigenicity and immunogenicity than over-expressed tumor self-antigens, for the potential valuable benefit of thousands of cancer patients around the World. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Ragone, Mauriello, Cavalluzzo, Cavalcanti, Russo, Manolio, Mangano, Cembrola, Tagliamonte and Buonaguro.) |
| References: | J Exp Med. 2002 Jul 15;196(2):207-16. (PMID: 12119345) Nature. 2020 Aug;584(7821):457-462. (PMID: 32668444) Lancet. 2021 Mar 27;397(10280):1229-1236. (PMID: 33711296) Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444) Sci Immunol. 2019 Jul 19;4(37):. (PMID: 31324690) Front Immunol. 2023 Jan 10;13:1035344. (PMID: 36703960) Science. 2020 Mar 27;367(6485):1444-1448. (PMID: 32132184) Front Immunol. 2021 Jul 27;12:734689. (PMID: 34386018) J Immunother Cancer. 2021 May;9(5):. (PMID: 34049932) Nat Commun. 2021 May 10;12(1):2593. (PMID: 33972535) Nat Rev Immunol. 2012 Sep;12(9):669-77. (PMID: 22918468) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) J Biol Chem. 2012 Jan 6;287(2):1168-77. (PMID: 22102287) Immunity. 2020 Nov 17;53(5):1095-1107.e3. (PMID: 33128877) iScience. 2022 Dec 22;25(12):105479. (PMID: 36338436) Immunity. 2021 Mar 9;54(3):586-602.e8. (PMID: 33691136) Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127) Cell Stress Chaperones. 2021 Jul;26(4):611-616. (PMID: 33977496) Sci Immunol. 2022 Jan 21;7(67):eabk3070. (PMID: 34793243) J Transl Med. 2022 Jul 14;20(1):316. (PMID: 35836198) Sci Immunol. 2020 Jun 26;5(48):. (PMID: 32591408) J Transl Med. 2022 Oct 15;20(1):472. (PMID: 36243758) Mol Cancer. 2023 Apr 26;22(1):75. (PMID: 37101139) J Exp Med. 1996 Aug 1;184(2):647-57. (PMID: 8760818) N Engl J Med. 2021 Nov 4;385(19):1761-1773. (PMID: 34525277) Infect Agent Cancer. 2021 May 12;16(1):32. (PMID: 33980271) J Exp Med. 1999 Sep 6;190(5):705-15. (PMID: 10477554) Cancers (Basel). 2021 Dec 28;14(1):. (PMID: 35008303) Mol Aspects Med. 2023 Aug;92:101192. (PMID: 37295175) Nature. 2020 Nov;587(7833):270-274. (PMID: 32726801) N Engl J Med. 2022 May 19;386(20):1910-1921. (PMID: 35320659) Front Oncol. 2022 Oct 18;12:1009247. (PMID: 36330482) J Transl Med. 2018 Oct 19;16(1):286. (PMID: 30340600) J Immunol. 2002 Nov 15;169(10):5696-707. (PMID: 12421949) Nature. 2021 Jul;595(7868):572-577. (PMID: 34044428) Cell. 2021 Apr 29;184(9):2332-2347.e16. (PMID: 33761326) |
| فهرسة مساهمة: | Keywords: (TAA) tumor-associated antigen; SARS-CoV-2; T cell cross reactivity; cancer vaccine; molecular mimicry |
| المشرفين على المادة: | 0 (Epitopes, T-Lymphocyte) 0 (BNT162 Vaccine) 0 (Antigens, Viral) 0 (HLA-A2 Antigen) 0 (Antigens, Neoplasm) 0 (COVID-19 Vaccines) |
| تواريخ الأحداث: | Date Created: 20240701 Date Completed: 20240701 Latest Revision: 20240702 |
| رمز التحديث: | 20240702 |
| مُعرف محوري في PubMed: | PMC11211543 |
| DOI: | 10.3389/fimmu.2024.1398002 |
| PMID: | 38947322 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1398002 |